{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T07:40:31Z","timestamp":1655538031906},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s15006-016-8061-z","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T07:41:07Z","timestamp":1460619667000},"page":"46-50","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wie hoch ist der Patientennutzen wirklich?"],"prefix":"10.1007","volume":"158","author":[{"given":"Thorsten","family":"Siegmund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"key":"8061_CR1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"H.C. Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545\u20132559","journal-title":"N Engl J Med"},{"issue":"1","key":"8061_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"S.E. Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"issue":"22","key":"8061_CR3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B. Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"8061_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2013.03.003","volume":"73","author":"K. Kostev","year":"2013","unstructured":"Kostev K, Rathmann W. Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). Prim Care Diabetes. 2013;7(3):229\u201333.","journal-title":"Prim Care Diabetes"},{"issue":"10","key":"8061_CR5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1060028015597915","volume":"49","author":"J. Goldman","year":"2015","unstructured":"Goldman J, White JR Jr. New Insulin Glargine 300 U\/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Ann Pharmacother. 2015;49(10):1153\u201361.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"8061_CR6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"R.E. Ratner","year":"2013","unstructured":"Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"8061_CR7","first-page":"1514","volume":"370","author":"E.W. Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med 2014; 370: 1514\u20131523","journal-title":"1990\u20132010"},{"key":"8061_CR8","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854\u2013865","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"8061_CR9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","volume":"28","author":"D.T. Eurich","year":"2005","unstructured":"Eurich DT, Majumdar SR, McAlister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345\u20132351","journal-title":"Diabetes Care"},{"key":"8061_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","volume":"6","author":"D.T. Eurich","year":"2013","unstructured":"Eurich DT, Weir DL, Majumdar SR et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circulation Heart failure 2013; 6: 395\u2013402","journal-title":"Circulation Heart failure"},{"issue":"22","key":"8061_CR11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1055\/s-0032-1333023","volume":"138","author":"G. Rudofsky","year":"2013","unstructured":"Rudofsky G, R\u00fcssmann HJ, Siegmund T. [SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?]. Dtsch Med Wochenschr. 2013;138(22):1172\u20137.","journal-title":"Dtsch Med Wochenschr"},{"key":"8061_CR12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"J.J. Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728\u2013742","journal-title":"Nat Rev Endocrinol"},{"issue":"23","key":"8061_CR13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"M.A. Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"8061_CR14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","volume":"166","author":"S.P. Marso","year":"2013","unstructured":"Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823\u201330.","journal-title":"Am Heart J"},{"key":"8061_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"J.R. Ussher","year":"2012","unstructured":"Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187\u2013215","journal-title":"Endocr Rev"},{"key":"8061_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1586\/erc.12.5","volume":"10","author":"C.F. Deacon","year":"2012","unstructured":"Deacon CF, Marx N. Potential cardiovascular effects of incretin-based therapies. Expert Rev Cardiovasc Ther 2012; 10: 337\u2013351","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"8061_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2011.12.007","volume":"167","author":"B. Hocher","year":"2013","unstructured":"Hocher B, Sharkovska Y, Mark M et al. The novel DPP-4 inhibitors linagliptin and BI 14 361 reduce infarct size after myocardial ischemia \/ reperfusion in rats. Int J Cardiol 2013; 167: 87\u201393","journal-title":"Int J Cardiol"},{"key":"8061_CR18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","volume":"15","author":"M. Monami","year":"2013","unstructured":"Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 112\u2013120","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"8061_CR19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"B.M. Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"key":"8061_CR20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"W.B. White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327\u20131335.","journal-title":"N Engl J Med"},{"issue":"3","key":"8061_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"J.B. Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"8061_CR22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","volume":"38","author":"J.A. Udell","year":"2015","unstructured":"Udell JA, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee andInvestigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696\u2013705.","journal-title":"Diabetes Care"},{"issue":"4","key":"8061_CR23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dme.12703","volume":"32","author":"R.E. Ryder","year":"2015","unstructured":"Ryder RE. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Diabet Med. 2015;32(4):438\u20139.","journal-title":"Diabet Med"},{"issue":"2","key":"8061_CR24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diabres.2012.09.001","volume":"98","author":"A.J. Scheen","year":"2012","unstructured":"Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract. 2012;98(2):175\u201386.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"8061_CR25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/dom.12608","volume":"18","author":"E. Erdmann","year":"2016","unstructured":"Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18(3):266\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"8061_CR26","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1161\/01.CIR.0000015076.37047.D9","volume":"105","author":"J.N. Bella","year":"2002","unstructured":"Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002;105(16):1928\u201333.","journal-title":"Circulation"},{"key":"8061_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12181-015-0035-3","volume":"10","author":"H. Bibra von","year":"2016","unstructured":"von Bibra H, Paulus P. Diastolische Dysfunktion. Echokardiographische Erfassung, \u00c4tiologie und Therapieans\u00e4tze. Kardiologe 2016 \u2022 10:47\u201355","journal-title":"Kardiologe"},{"issue":"1","key":"8061_CR28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-015-0320-2","volume":"15","author":"H. Bibra von","year":"2016","unstructured":"von Bibra H, Siegmund T, Kingreen I, et al. Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study. Cardiovasc Diabetol. 2016;15(1):7.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"8061_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0041-109122","volume":"141","author":"P. Heilmeyer","year":"2016","unstructured":"Heilmeyer P, von Bibra H. Diastolic heart failure treated by diet. Dtsch Med Wochenschr. 2016;141(2):121\u20134.","journal-title":"Dtsch Med Wochenschr"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-016-8061-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15006-016-8061-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-016-8061-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:53:45Z","timestamp":1655495625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-016-8061-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["8061"],"URL":"https:\/\/doi.org\/10.1007\/s15006-016-8061-z","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}